Transgene’s therapeutic vaccine candidate TG4001 has flunked a phase 2 solid tumor trial. But, while the prospect failed to improve progression-free survival (PFS), the French biotech is ...

Transgene and ProBioGen, a CDMO, inked a license agreement for ProBioGen’s AGE1.CR.pIX ® suspension cell line which will combine ProBioGen’s specific production technology with the ...

Transgene's therapeutic vaccine for cervical and anogenital cancers has failed a phase 2 trial, but an efficacy signal warrants further study, says the company. The French biotech's study of ...

Phase 2 study of TG4001 shows promise in cervical cancer patients Transgene, a biotech company specializing in virus-based immunotherapies for cancer, has announced that its phase 2 trial of TG4001 in ...

Given the considerable time and effort companies have invested in gene therapy, most prefer to play it safe when it comes to manufacturing. Accordingly, the large majority of recombinant adeno ...

STRASBOURG, France and BERLIN, Germany, November 05, 2024 / Biotech Newswire / -- Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the ...